

Simona Guerzoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2197901/publications.pdf>

Version: 2024-02-01

44
papers

1,249
citations

471061

17
h-index

360668

35
g-index

44
all docs

44
docs citations

44
times ranked

1612
citing authors

#	ARTICLE	IF	CITATIONS
1	Paracetamol: New Vistas of an Old Drug. <i>CNS Neuroscience & Therapeutics</i> , 2006, 12, 250-275.	4.0	460
2	Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial. <i>Journal of Headache and Pain</i> , 2012, 13, 677-684.	2.5	67
3	Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 534-547.	0.8	56
4	Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment. <i>Journal of Headache and Pain</i> , 2016, 17, 48.	2.5	49
5	Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy. <i>Frontiers in Neurology</i> , 2017, 8, 586.	1.1	42
6	A genome-wide analysis in cluster headache points to neprilysin and PACAP receptor gene variants. <i>Journal of Headache and Pain</i> , 2016, 17, 114.	2.5	38
7	Impact of continuing or quitting smoking on episodic cluster headache: a pilot survey. <i>Journal of Headache and Pain</i> , 2013, 14, 48.	2.5	35
8	Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal. <i>Journal of Headache and Pain</i> , 2017, 18, 71.	2.5	34
9	Predictors of response to erenumab after 12 months of treatment. <i>Brain and Behavior</i> , 2021, 11, e2260.	1.0	34
10	Basal cutaneous pain threshold in headache patients. <i>Journal of Headache and Pain</i> , 2011, 12, 303-310.	2.5	30
11	Drug-drug interactions in the treatment for alcohol use disorders: A comprehensive review. <i>Pharmacological Research</i> , 2018, 133, 65-76.	3.1	30
12	Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache. <i>Neurological Sciences</i> , 2022, 43, 1273-1280.	0.9	28
13	Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH): a pilot study. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1427-1436.	0.8	27
14	Serum protein changes in a rat model of chronic pain show a correlation between animal and humans. <i>Scientific Reports</i> , 2017, 7, 41723.	1.6	26
15	Comparison of tolerability and efficacy of a combination of paracetamol+caffeine and sumatriptan in the treatment of migraine attack: a randomized, double-blind, double-dummy, cross-over study. <i>Journal of Headache and Pain</i> , 2012, 13, 669-675.	2.5	22
16	Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data. <i>Journal of Headache and Pain</i> , 2020, 21, 40.	2.5	22
17	Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache. <i>Cephalalgia</i> , 2022, 42, 645-653.	1.8	20
18	Pharmacokinetics and pharmacodynamics of new acute treatments for migraine. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 189-198.	1.5	19

#	ARTICLE	IF	CITATIONS
19	Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study. <i>Journal of Headache and Pain</i> , 2022, 23, 38.	2.5	18
20	A Critical Evaluation on MOH Current Treatments. <i>Current Treatment Options in Neurology</i> , 2017, 19, 32.	0.7	17
21	Proteomic analysis of urine in medication-overuse headache patients: possible relation with renal damages. <i>Journal of Headache and Pain</i> , 2012, 13, 45-52.	2.5	15
22	Discovery by a proteomic approach of possible early biomarkers of drug-induced nephrotoxicity in medication-overuse headache. <i>Journal of Headache and Pain</i> , 2013, 14, 6.	2.5	15
23	Validation of potential candidate biomarkers of drug-induced nephrotoxicity and allodynia in medication-overuse headache. <i>Journal of Headache and Pain</i> , 2015, 16, 559.	2.5	14
24	Gender Differences in 3-Month Outcomes of Erenumab Treatmentâ€”Study on Efficacy and Safety of Treatment With Erenumab in Men. <i>Frontiers in Neurology</i> , 2021, 12, 774341.	1.1	14
25	Nabilone administration in refractory chronic diarrhea: a case series. <i>BMC Gastroenterology</i> , 2019, 19, 105.	0.8	13
26	Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study. <i>Pain and Therapy</i> , 2021, 10, 637-650.	1.5	12
27	Chronic migraine evolution after 3Âmonths from erenumab suspension: real-world-evidence-life data. <i>Neurological Sciences</i> , 2022, 43, 3823-3830.	0.9	11
28	Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006, 2, 981-1007.	1.5	9
29	Rare primary headaches in Italian tertiary Headache Centres: Three year nationwide retrospective data from the RegistRare Network. <i>Cephalalgia</i> , 2018, 38, 1429-1441.	1.8	9
30	Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients. <i>Pain and Therapy</i> , 2021, 10, 1605-1618.	1.5	8
31	The association between onabotulinumtoxinA and anti-CGRP monoclonal antibodies: a reliable option for the optimal treatment of chronic migraine. <i>Neurological Sciences</i> , 2022, 43, 5687-5695.	0.9	8
32	Nummular headache: a gender-oriented perspective on a case series from the RegistRare Network. <i>Neurological Sciences</i> , 2020, 41, 583-589.	0.9	7
33	Clinical Evidence of Cannabinoids in Migraine: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 1479.	1.0	7
34	<p>Once-monthly galcanezumab for the prevention of migraine in adults: an evidence-based descriptive review and potential place in therapy</p>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 557-569.	0.9	6
35	Identification of candidate proteomic markers in the serum of medication overuse headache patients: An exploratory study. <i>Cephalalgia</i> , 2020, 40, 1070-1078.	1.8	6
36	Chronic Migraine and Medication Overuse Headache Worsening After OnabotulinumtoxinA Withdrawn Due to the Severe Acute Respiratory Syndrome-Coronavirus-2 Pandemic. <i>Frontiers in Neurology</i> , 2021, 12, 647995.	1.1	5

#	ARTICLE	IF	CITATIONS
37	Oral Cannabinoid Preparations for the Treatment of Chronic Migraine: A Retrospective Study. <i>Pain Medicine</i> , 2022, 23, 396-402.	0.9	5
38	A case-control study of visually evoked postural responses in childhood with primary headaches. <i>Neurological Sciences</i> , 2020, 41, 305-311.	0.9	4
39	Exploration of candidate serum biomarkers potentially related to the chronic pain condition in Medication-overuse headache. <i>BMC Neurology</i> , 2019, 19, 239.	0.8	3
40	Easy tools to screen Italian women suffering from migraine with and without aura in early reproductive age. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2019, 242, 63-67.	0.5	3
41	Occlusal splint therapy in patients with MÃ©niÃ©re's disease and temporomandibular joint disorder. <i>Acta Otorhinolaryngologica Italica</i> , 2022, , 1-8.	0.7	1
42	Proteomic research of proteins involved in pain expression in an animal model of chronic pain. <i>Journal of Headache and Pain</i> , 2015, 16, A8.	2.5	0
43	Addendum: Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy. <i>Frontiers in Neurology</i> , 2018, 9, .	1.1	0
44	Response to: "Drugs for treatment for alcohol use disorders expose to interactions with others" for little benefit if any. <i>Pharmacological Research</i> , 2018, 134, 220.	3.1	0